{"count": 9, "results": [{"_id": "34383728", "pmid": 34383728, "pmcid": "PMC8369431", "title": "Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury", "journal": "Am J Case Rep", "authors": ["Alanazi NS", "Alenazi TS", "Alenzi KA"], "date": "2021-08-12T00:00:00Z", "doi": "10.12659/AJCR.931418", "meta_date_publication": "2021 Aug 12", "meta_volume": "22", "meta_issue": "", "meta_pages": "e931418", "score": 50251.17, "text_hl": "We describe the case of a 69-year-old Saudi man with a medical history of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@ and @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@ for 2 years, on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Gliclazide @CHEMICAL_MESH:D005907 @@@gliclazide@@@ modified release, daily @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@, and @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@. ", "citations": {"NLM": "Alanazi NS, Alenazi TS, Alenzi KA. Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury Am J Case Rep. 2021 Aug 12;22():e931418. PMID: 34383728", "BibTeX": "@article{34383728, title={Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury}, author={Alanazi NS and Alenazi TS and Alenzi KA}, journal={Am J Case Rep}, volume={22}, pages={e931418}}"}}, {"_id": "32601121", "pmid": 32601121, "title": "Association of prestroke metformin use, stroke severity, and thrombolysis outcome.", "journal": "Neurology", "authors": ["Westphal LP", "Widmer R", "Held U", "Steigmiller K", "Hametner C", "Ringleb P", "Curtze S", "Martinez-Majander N", "Tiainen M", "Nolte CH", "Scheitz JF", "Erdur H", "Polymeris AA", "Traenka C", "Eskandari A", "Michel P", "Heldner MR", "Arnold M", "Zini A", "Vandelli L", "Coutinho JM", "Groot AE", "Padjen V", "Jovanovic DR", "Bejot Y", "Brenière C", "Turc G", "Seners P", "Pezzini A", "Magoni M", "Leys D", "Gilliot S", "Scherrer MJ", "Kägi G", "Luft AR", "Gensicke H", "Nederkoorn P", "Tatlisumak T", "Engelter ST", "Wegener S", "Thrombolysis in Ischemic Stroke Patients (TRISP) Study Group"], "date": "2020-07-28T00:00:00Z", "doi": "10.1212/WNL.0000000000009951", "meta_date_publication": "2020 Jul 28", "meta_volume": "95", "meta_issue": "4", "meta_pages": "e362-e373", "score": 50250.395, "text_hl": "@<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@Hypercholesterolemia@@@ and pretreatment with statins, antiplatelets, or antihypertensives were more common in the @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@+ group. ", "citations": {"NLM": "Westphal LP, Widmer R, Held U, Steigmiller K, Hametner C, Ringleb P, Curtze S, Martinez-Majander N, Tiainen M, Nolte CH, Scheitz JF, Erdur H, Polymeris AA, Traenka C, Eskandari A, Michel P, Heldner MR, Arnold M, Zini A, Vandelli L, Coutinho JM, Groot AE, Padjen V, Jovanovic DR, Bejot Y, Brenière C, Turc G, Seners P, Pezzini A, Magoni M, Leys D, Gilliot S, Scherrer MJ, Kägi G, Luft AR, Gensicke H, Nederkoorn P, Tatlisumak T, Engelter ST, Wegener S, Thrombolysis in Ischemic Stroke Patients (TRISP) Study Group. Association of prestroke metformin use, stroke severity, and thrombolysis outcome. Neurology. 2020 Jul 28;95(4):e362-e373. PMID: 32601121", "BibTeX": "@article{32601121, title={Association of prestroke metformin use, stroke severity, and thrombolysis outcome.}, author={Westphal LP and Widmer R and Held U and Steigmiller K and Hametner C and Ringleb P and Curtze S and Martinez-Majander N and Tiainen M and Nolte CH and Scheitz JF and Erdur H and Polymeris AA and Traenka C and Eskandari A and Michel P and Heldner MR and Arnold M and Zini A and Vandelli L and Coutinho JM and Groot AE and Padjen V and Jovanovic DR and Bejot Y and Brenière C and Turc G and Seners P and Pezzini A and Magoni M and Leys D and Gilliot S and Scherrer MJ and Kägi G and Luft AR and Gensicke H and Nederkoorn P and Tatlisumak T and Engelter ST and Wegener S and Thrombolysis in Ischemic Stroke Patients (TRISP) Study Group}, journal={Neurology}, volume={95}, number={4}, pages={e362-e373}}"}}, {"_id": "35237909", "pmid": 35237909, "title": "Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.", "journal": "Endocrine", "authors": ["Ali A", "Unnikannan H", "Shafarin J", "Bajbouj K", "Taneera J", "Muhammad JS", "Hasan H", "Salehi A", "Awadallah S", "Hamad M"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s12020-022-03022-x", "meta_date_publication": "2022 Jun", "meta_volume": "76", "meta_issue": "3", "meta_pages": "543-557", "score": 50245.33, "text_hl": "CONCLUSIONS: These findings suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MF@@@ treatment reduces circulating LDL-C levels by suppressing @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ expression and enhancing @GENE_LDLR @GENE_3949 @@@LDLR@@@ expression; hence the potential therapeutic utility of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MF@@@ in @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@.", "citations": {"NLM": "Ali A, Unnikannan H, Shafarin J, Bajbouj K, Taneera J, Muhammad JS, Hasan H, Salehi A, Awadallah S, Hamad M. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells. Endocrine. 2022 Jun;76(3):543-557. PMID: 35237909", "BibTeX": "@article{35237909, title={Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.}, author={Ali A and Unnikannan H and Shafarin J and Bajbouj K and Taneera J and Muhammad JS and Hasan H and Salehi A and Awadallah S and Hamad M}, journal={Endocrine}, volume={76}, number={3}, pages={543-557}}"}}, {"_id": "39950294", "pmid": 39950294, "title": "Sars-Cov-2 Infection as Catecholamin Crisis in Pheocreomocitoma: A Case Report.", "journal": "Endocr Metab Immune Disord Drug Targets", "authors": ["Novizio R", "Corsello A", "Rizzo GE", "Pontecorvi A", "Locantore P"], "date": "2025-02-10T00:00:00Z", "doi": "10.2174/0118715303348376250103113426", "meta_date_publication": "2025 Feb 10", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50222.445, "text_hl": "The @SPECIES_9606 @@@patient@@@ had a known medical history of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 mellitus diabetes@@@ and @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@ treated by slow-release @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ 500 mg/day and @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ 40 mg/day and was not vaccinated for @SPECIES_2697049 @@@Sars-CoV-2@@@. ", "citations": {"NLM": "Novizio R, Corsello A, Rizzo GE, Pontecorvi A, Locantore P. Sars-Cov-2 Infection as Catecholamin Crisis in Pheocreomocitoma: A Case Report. Endocr Metab Immune Disord Drug Targets. 2025 Feb 10;():. PMID: 39950294", "BibTeX": "@article{39950294, title={Sars-Cov-2 Infection as Catecholamin Crisis in Pheocreomocitoma: A Case Report.}, author={Novizio R and Corsello A and Rizzo GE and Pontecorvi A and Locantore P}, journal={Endocr Metab Immune Disord Drug Targets}}"}}, {"_id": "2291838", "pmid": 2291838, "title": "Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial.", "journal": "Ann Med", "authors": ["Pentikäinen PJ", "Voutilainen E", "Aro A", "Uusitupa M", "Penttilä I", "Vapaatalo H"], "date": "1990-01-01T00:00:00Z", "doi": "10.3109/07853899009147912", "meta_date_publication": "1990", "meta_volume": "22", "meta_issue": "5", "meta_pages": "307-12", "score": 50046.254, "text_hl": "The reduction of total- and LDL-cholesterol levels may be a welcome additional consequence of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ during treatment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@.", "citations": {"NLM": "Pentikäinen PJ, Voutilainen E, Aro A, Uusitupa M, Penttilä I, Vapaatalo H. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med. 1990;22(5):307-12. PMID: 2291838", "BibTeX": "@article{2291838, title={Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial.}, author={Pentikäinen PJ and Voutilainen E and Aro A and Uusitupa M and Penttilä I and Vapaatalo H}, journal={Ann Med}, volume={22}, number={5}, pages={307-12}}"}}, {"_id": "29211033", "pmid": 29211033, "pmcid": "PMC5745512", "title": "In Vitro and In Vivo Antioxidant and Anti-Hyperglycemic Activities of Moroccan Oat Cultivars", "journal": "Antioxidants (Basel)", "authors": ["Marmouzi I", "Karym EM", "Saidi N", "Meddah B", "Kharbach M", "Masrar A", "Bouabdellah M", "Chabraoui L", "El Allali K", "Cherrah Y", "Faouzi MEA"], "date": "2017-12-06T00:00:00Z", "doi": "10.3390/antiox6040102", "meta_date_publication": "2017 Dec 6", "meta_volume": "6", "meta_issue": "4", "meta_pages": "", "score": 50044.594, "text_hl": "Whereas animals in group @CHEMICAL_Methionine @CHEMICAL_MESH:D008715 @@@Met@@@ were given @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (300 mg/kg). ", "citations": {"NLM": "Marmouzi I, Karym EM, Saidi N, Meddah B, Kharbach M, Masrar A, Bouabdellah M, Chabraoui L, El Allali K, Cherrah Y, Faouzi MEA. In Vitro and In Vivo Antioxidant and Anti-Hyperglycemic Activities of Moroccan Oat Cultivars Antioxidants (Basel). 2017 Dec 6;6(4):. PMID: 29211033", "BibTeX": "@article{29211033, title={In Vitro and In Vivo Antioxidant and Anti-Hyperglycemic Activities of Moroccan Oat Cultivars}, author={Marmouzi I and Karym EM and Saidi N and Meddah B and Kharbach M and Masrar A and Bouabdellah M and Chabraoui L and El Allali K and Cherrah Y and Faouzi MEA}, journal={Antioxidants (Basel)}, volume={6}, number={4}}"}}, {"_id": "20634175", "pmid": 20634175, "title": "Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.", "journal": "Endocr Pract", "authors": ["Rosenstock J", "Fonseca VA", "Garvey WT", "Goldberg RB", "Handelsman Y", "Abby SL", "Lai YL", "Jin X", "Misir S", "Nagendran S", "Jones MR"], "date": "2010-07-01T00:00:00Z", "doi": "10.4158/EP10130.OR", "meta_date_publication": "2010 Jul-Aug", "meta_volume": "16", "meta_issue": "4", "meta_pages": "629-40", "score": 50041.51, "text_hl": "METHODS: In this 16-week, randomized, double-blind, placebo-controlled study, adults with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ (hemoglobin A1c [@VARIANT_c.1A>C_APOA1_human @VARIANT_tmVar:c|SUB|A|1|C;HGVS:c.1A>C;VariantGroup:0;CorrespondingGene:335;CorrespondingSpecies:9606 @@@A1C@@@] values of 6.5% to 10.0%) and @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@ (low-density lipoprotein cholesterol [LDL-C] levels > or =100 mg/dL) were randomly assigned (1:1) to @CHEMICAL_Colesevelam_Hydrochloride @CHEMICAL_MESH:D000069472 @@@colesevelam@@@ (3.75 g/d) or placebo in combination with open-label @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (850 mg/d; uptitrated at week 2 to 1,700 mg/d). ", "citations": {"NLM": "Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug;16(4):629-40. PMID: 20634175", "BibTeX": "@article{20634175, title={Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.}, author={Rosenstock J and Fonseca VA and Garvey WT and Goldberg RB and Handelsman Y and Abby SL and Lai YL and Jin X and Misir S and Nagendran S and Jones MR}, journal={Endocr Pract}, volume={16}, number={4}, pages={629-40}}"}}, {"_id": "29572114", "pmid": 29572114, "title": "Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.", "journal": "Biochim Biophys Acta Mol Basis Dis", "authors": ["Jaikumkao K", "Pongchaidecha A", "Chueakula N", "Thongnak L", "Wanchai K", "Chatsudthipong V", "Chattipakorn N", "Lungkaphin A"], "date": "2018-06-01T00:00:00Z", "doi": "10.1016/j.bbadis.2018.03.017", "meta_date_publication": "2018 Jun", "meta_volume": "1864", "meta_issue": "6 Pt A", "meta_pages": "2021-2033", "score": 50038.914, "text_hl": "@CHEMICAL_dapagliflozin @CHEMICAL_MESH:C529054 @@@Dapagliflozin@@@ or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment decreased @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@, @CHEMICAL_Creatinine @CHEMICAL_MESH:D003404 @@@creatinine@@@ clearance and renal oxidative stress leading to improved renal function. ", "citations": {"NLM": "Jaikumkao K, Pongchaidecha A, Chueakula N, Thongnak L, Wanchai K, Chatsudthipong V, Chattipakorn N, Lungkaphin A. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt A):2021-2033. PMID: 29572114", "BibTeX": "@article{29572114, title={Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.}, author={Jaikumkao K and Pongchaidecha A and Chueakula N and Thongnak L and Wanchai K and Chatsudthipong V and Chattipakorn N and Lungkaphin A}, journal={Biochim Biophys Acta Mol Basis Dis}, volume={1864}, number={6 Pt A}, pages={2021-2033}}"}}, {"_id": "28129400", "pmid": 28129400, "pmcid": "PMC5271369", "title": "Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies", "journal": "PLoS One", "authors": ["Okoduwa SI", "Umar IA", "James DB", "Inuwa HM"], "date": "2017-01-27T00:00:00Z", "doi": "10.1371/journal.pone.0170971", "meta_date_publication": "2017", "meta_volume": "12", "meta_issue": "1", "meta_pages": "e0170971", "score": 50027.95, "text_hl": "These @CELLLINE_CVCL:4630 @@@FDF35@@@ @SPECIES_10116 @@@rats@@@ were sensitive to @CHEMICAL_Glyburide @CHEMICAL_MESH:D005905 @@@glibenclamide@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ in lowering hyperglycaemia, @DISEASE_Hypertriglyceridemia @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@ and @<m>DISEASE_Hypercholesterolemia</m> @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@", "citations": {"NLM": "Okoduwa SI, Umar IA, James DB, Inuwa HM. Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies PLoS One. 2017;12(1):e0170971. PMID: 28129400", "BibTeX": "@article{28129400, title={Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies}, author={Okoduwa SI and Umar IA and James DB and Inuwa HM}, journal={PLoS One}, volume={12}, number={1}, pages={e0170971}}"}}]}